Use of cpg as an adjuvant for malaria vaccine

Details Use of cpg as an adjuvant for malaria vaccine Use of cpg as an adjuvant for malaria vaccine

A - Human Necessities

61

K

A61K 39/39 (2006.01) A61K 39/005 (2006.01) A61K 39/015 (2006.01) A61P 33/06 (2006.01)

Patent

CA 2376926

A vaccine formulation for the prevention or amelioration of plasmodium infection in humans is provided. The vaccine comprises a malaria antigen, especially a protein which comprises a portion of the CS protein of P. falciparum fused in frame via a linear linker to the N-terminal of HBsAg, and an immunostimulatory CpG oligonucleotide. Methods for making the vaccine formulation of the invention are described. Patients may also be treated by pre-administration of the CpG oligonucleotide prior to administration of the malaria antigen.

La présente invention concerne une formulation de vaccin destinée à prévenir ou à soulager les infections à Plasmodium chez les humains. Le vaccin de l'invention comprend un antigène de la malaria, en particulier une protéine qui comprend une partie de la protéine CS de P. falciparum fusionnée en phase via une séquence de liaison linéaire à l'extrémité N-terminale de HbsAg, et un oligonucléotide CpG immunostimulant. L'invention se rapporte également à des procédés de fabrication de la formulation de vaccin de l'invention. On peut également traiter les patients en leur administrant l'oligonucléotide CpG avant de leur administrer l'antigène de la malaria.

Affiliated with

Also associated with

Rating

Use of cpg as an adjuvant for malaria vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of cpg as an adjuvant for malaria vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cpg as an adjuvant for malaria vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2017515